-
Evommune nabs $150M in IPO amid federal shutdown
06 Nov 2025 05:41 GMT
… , priced a $150 million initial public offering on Wednesday.
The Palo Alto … a newly approved therapy from Novartis, is associated with certain side … , afterwards.
Prior to its IPO, Evommune had raised $267 … two dozen that had priced IPOs by this time last …
-
Novartis Slips As Generics Champ At Heart-Failure Drug In Mixed Third Quarter
28 Oct 2025 13:20 GMT
… .
Analysts polled by FactSet expected Novartis to earn $2.27 a … .
During the year-earlier period, Novartis earned $2.06 per share … -point hit on Entresto sales, Novartis said in its news release … To Buy And Watch: Top IPOs, Big And Small Caps, Growth …
-
USA Rare Earth, Iren, Novartis, Softbank: Trending Stocks
27 Oct 2025 12:38 GMT
… might be preparing for an IPO there.
01:21 Speaker A … :26 Speaker A
Swiss giant Novartis is making a big move … neuroscience.
01:41 Speaker A
Novartis shares are slightly lower this …
-
In Novartis patent case, India has a BIT of cover
22 Sep 2025 18:35 GMT
… Office (IPO) has revoked the patent of Novartis for … market, benefiting patients. Novartis may challenge this revocation … having jurisdiction, if Novartis challenges this patent revocation … expectations. So, could Novartis have the legitimate expectation …
-
Novartis Loses India Patent on Heart Failure Drug Vymada
19 Sep 2025 04:56 GMT
… Also Read:Interim relief to Novartis: Delhi HC reinstates Entresto … its order, the IPO noted that Novartis had failed to … and Eris Lifesciences following Novartis’ lawsuits. Several firms had … also noted that while Novartis’ earlier sacubitril–valsartan patent …
-
Novartis dives deeper into protein degraders with second Monte Rosa deal
15 Sep 2025 17:47 GMT
… and early testing before Novartis takes over development for … following a $222 million initial public offering in 2021.
Monte Rosa … as traditional drugs do.
Novartis has been particularly active … of biomedical research at Novartis, in a statement. Marshall …
-
Patent Office Revokes Patent for Novartis’ Cardiac Drug
17 Sep 2025 13:24 GMT
… but courts restrained them following Novartis’ legal action. With the … enhanced therapeutic efficacy. Notably, Novartis had earlier lost its patent … under the same clause.
IPO’s Ruling
Usha Rao, … efficacy.”
High Stakes for Novartis
Vymada is a major revenue …
-
SIJ Acroni, Novartis and national chemistry institute among leading innovators
17 Sep 2025 12:10 GMT
Pharma companies Novartis, Krka and Lek, the National … SMARTI iCon wood scanner.
Iskra Ipo received the gold award for … in drinking and bathing waters.
Novartis and Keko - Oprema also …
-
Why India revoked patent of Novartis’ cardiac drug and why it matters
16 Sep 2025 18:36 GMT
… revoked the patent on Novartis’ cardiac drug Entresto, sold … , opposed the patent on Novartis’ heart-failure drug Vymada. … The Indian Pharmaceutical Alliance opposed Novartis’ patent on Vymada. File … the IPO’s decision in court. “The patentee (Novartis) abstained …
-
In major move, patent of Novartis' blockbuster cardiac drug revoked by India
16 Sep 2025 07:35 GMT
… Patent Office (IPO) has revoked the patent on Novartis’ blockbuster therapy … and heart failure. For Novartis, the drug is a … access to affordable medicines.
Novartis’ patent, filed in 2007 …
Legal observers noted that Novartis abstained from the final …